Peritransplant toxicity and a delay in effective immune reconstitution have limited the utility of alternate donor transplantation for children with refractory severe aplastic anemia. We have assessed the effectiveness of infusing large numbers of highly purified haploidentical CD34 þ cells after immunoablative conditioning in three patients who had failed intensive immunosuppression, lacked unrelated donors, and had active or recent serious infections. One patient rejected the first infusion, but engrafted after a second infusion from the same donor. This patient died 4 months after hematopoietic stem cell transplantation with no evidence of lymphoid reconstitution. Two patients experienced mixed chimerism requiring treatment with antibodies and/or donor lymphocyte infusion. Both currently survive more than 1 year after transplantation with normal blood counts, 100% donor engraftment, effective lymphoid reconstitution, and no chronic graft-versus-host disease. We observed functional thymopoiesis as measured by lymphocyte immunophenotyping, T cell receptor excision circles and T cell receptor Vb spectratyping complexity analysis. Further study is required to validate the initial promise of these preliminary observations.
Peritransplant toxicity and a delay in effective immune reconstitution have limited the utility of alternate donor transplantation for children with refractory severe aplastic anemia. We have assessed the effectiveness of infusing large numbers of highly purified haploidentical CD34 þ cells after immunoablative conditioning in three patients who had failed intensive immunosuppression, lacked unrelated donors, and had active or recent serious infections. One patient rejected the first infusion, but engrafted after a second infusion from the same donor. This patient died 4 months after hematopoietic stem cell transplantation with no evidence of lymphoid reconstitution. Two patients experienced mixed chimerism requiring treatment with antibodies and/or donor lymphocyte infusion. Both currently survive more than 1 year after transplantation with normal blood counts, 100% donor engraftment, effective lymphoid reconstitution, and no chronic graft-versus-host disease. We observed functional thymopoiesis as measured by lymphocyte immunophenotyping, T cell receptor excision circles and T cell receptor Vb spectratyping complexity analysis. Further study is required to validate the initial promise of these preliminary observations. Although matched sibling donor (MSD) hematopoietic stem cell transplantation (HSCT) is curative for greater than 80% of patients with severe aplastic anemia (SAA), most patients lack an HLA-matched sibling. Intensive immunosuppressive therapy (IST) for patients lacking MSD results in hematologic improvement in up to 75% of patients. For patients who fail IST, HSCT with a matched unrelated or haploidentical donor is an alternative. However, patients frequently lack matched unrelated donors, and overall survival is only 30-60% due to transplant-related complications, such as rejection, graft versus host disease (GVHD), and infection. [1] [2] [3] [4] [5] One report by Deeg et al 5 reported improved survival in patients transplanted with unrelated donors within one year of diagnosis with a cyclophosphamide and total body irradiation (TBI) regimen. This report sought to decrease toxicity by de-escalation of TBI when given in conjunction with cyclophosphamide. An alternate approach might be the infusion of large numbers of purified hematopoietic stem cells from haploidentical donors. [6] [7] [8] [9] [10] Historically, haploidentical transplantation has been limited due to increased rates of nonengraftment or graft rejection, GVHD, and transplant-related mortality compared to matched unrelated donor BMT. [11] [12] [13] [14] [15] [16] In adults with hematologic malignancies, this approach has led to a significant improvement in overall survival, the absence of severe GVHD (0%), and a low rate of rejection (o5%). 7 Reports of purified haploidentical transplantation in children show the feasibility of this approach for other disorders. 15, 17, 18 Successful haploidentical transplantation for SAA has been limited to two patients and no long-term data or immune reconstitution data are given. 19 Other attempts report death due to viral infection, nonengraftment, or toxicity. 9, 15, 20 To obtain preliminary experience on whether haploidentical BMT is feasible for SAA, we transplanted three children with refractory SAA who lacked suitable matched sibling and unrelated donors. We observed successful engraftment, one patient requiring two stem cell infusions, and no evidence of significant GVHD.
Delayed immune reconstitution is a problem after haploidentical transplantation, leading to an increased risk of opportunistic infections. One patient died of CMV pneumonitis 4 months after BMT with no evidence of lymphoid recovery. Two patients are alive and well 42 years after HSCT. We performed detailed analysis of immune reconstitution in the two surviving patients. These patients showed normal lymphoid populations, mitogen proliferation, and thymopoiesis by Vb-spectratyping and T cell receptor excision circles (TRECs). IgG production recovered to normal proportions and patients demonstrated antibody responses to tetanus and diphtheria after BMT.
Study design and methods

Patients
Three patients with refractory SAA were infused with peripheral blood stem cell grafts from haploidentical parental donors. HLA typing was performed by serology for HLA-A and -B, and by high-resolution DNA typing for HLA-DRB1. Patient 1 was matched for four of six antigens, while patients 2 and 3 were matched for three of six antigens. Patient characteristics and treatment are provided in Table 1 . No GVHD prophylaxis was administered post transplant. All patients had failed immunosuppression with ATG, cyclosporine, corticosteroids, and GM-CSF. All patients were heavily transfused prior to 
Transplant conditions
Donor peripheral blood stem cells were obtained after G-CSF administration (10 mg/kg/day Â 5-6 days). CD34 þ cells were selected utilizing the Miltenyi CliniMACS system. More than a 70% recovery of CD34 þ cells in all grafts processed, resulting in an infusion 8.5-56.5 Â 10 6 CD34 þ cells/kg with a CD34 þ purity of 490%, and a greater than 4 log depletion of CD3 þ cells (Table 1) , cyclophosphamide 200 mg/kg, and TLI 800 cGy. The dose of TLI was higher when used for reconditioning patient 1 due to the prior rejection and the patient's inability to tolerate additional high-dose cyclophosphamide because of multisystem organ dysfunction. All patients received OKT3 0.1 mg/kg from days þ 1 to þ 21 after transplantation. GM-CSF was administered until an ANC of 42000/ml was obtained for 2 consecutive days. Patients received IVIG 0.5 gm/kg weekly until day þ 100, then monthly until 9 months after transplantation.
Molecular analysis of T cell reconstitution
Peripheral blood mononuclear cells were analyzed for donor:host chimerism weekly until day 100 post transplant utilizing variable number of tandem repeat (VNTR) analysis (sensitivity 75%). TREC analysis was performed in duplicate by real-time PCR. 21 TCRb complementary determining region 3 (CDR3) size distribution was determined by reverse transcriptase polymerase chain reaction (RT-PCR) on an ABI Prism 310 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA), the data analyzed by Genescan software, and the overall complexity of TCRb subfamilies determined by spectratype complexity scoring.
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Results
Engraftment
Rapid donor neutrophil engraftment was obtained for all three patients, occurring at 11, 13, and 15 days, respectively. After initial neutrophil recovery at day þ 11, patient 1 developed acute rejection at day þ 17. This was characterized by the development of fever in excess of 401C, hepatosplenomegaly, and cardiopulmonary collapse, requiring mechanical ventilation and inotropic support. This patient was noted to have anti-HLA Class I antibodies directed against B44, a parental donor antigen. Despite treatment with high-dose corticosteroids, acute rejection and pancytopenia occurred. The patient was reconditioned, followed by a second CD34-selected graft from the same donor as described above. Prior to infusion of the second graft, the patient underwent plasmapheresis and rituximab therapy to reduce the anti-paternal HLA antibody. Stable full donor engraftment was obtained 12 days after the second infusion. Platelet engraftment occurred at days 16 and 18 for patients 2 and 3. Patient 1 died approximately 4 months after the second transplant of CMV pneumonitis. At the time of death, patient 1 had not obtained an unsupported platelet count of 420 000/ml.
Chimerism analysis
Serial VNTR analysis of peripheral blood in patient 1 demonstrated 100% donor engraftment after the second CD34 þ cell infusion. Patients 2 and 3 had initial chimerism of 100% donor at 2-3 weeks post transplant. Both developed mixed chimerism post transplant; patient 2 at 24 days and patient 3 at 55 days.
Approximately 2 weeks after HSCT, patient 2 developed persistent fever in excess of 391C raising concerns of acute rejection. OKT3 and GM-CSF were discontinued and a single dose of horse ATG (30 mg/kg) administered. Owing to a decline in the proportion of donor cells to 90% by 30 days after transplant, a 3 day course of Thymoglobulin (2.5 mg/kg/day) was given, followed by a 3 day course of CAMPATH (10 mg/m /kg donor CD3 þ cells were administered, leading to a steady increase in donor chimerism to 100% by day þ 132. No GVHD was observed.
In patient 3, a decline to 89% donor chimerism was noted at day þ 55, leading to infusion of 2.5 Â 10 4 /kg donor CD3 þ cells. No ATG or CAMPATH was administered to patient 3 due to lack of effect in patient 2. Peripheral blood chimerism continued to decline to a level of 27% donor cells, leading to a second donor lymphocyte infusion (DLI) of 2.5 Â 10 4 /kg CD3 þ cells. The peripheral blood mononuclear chimerism continued to increase to a level of 67% donor cells. A simultaneous T cell chimerism analysis revealed a level of 33% donor. Another DLI of 5.0 Â 10 4 CD3 þ cells/kg was administered. This intervention resulted in gradual improvement to 100% donor chimerism by 18 months after transplant.
GVHD
Despite the use of mismatched grafts, only one patient developed Grade I acute GVHD, which resolved with a short course of corticosteroids. No patient developed chronic GVHD.
Immune reconstitution
Serial immune reconstitution studies were performed in patients 2 and 3.
Quantitative recovery of lymphoid cells
CD19 þ B cells were the first lymphoid cells to recover. Normal CD19 þ cell counts (X0.1 Â 10 3 /ml) occurred at 84 and 152 days in patients 2 and 3, respectively. Natural killer (NK) cells (CD56 þ /16 þ ) reached normal levels (X0.1 Â 10 3 /ml) at days 138 and 152, respectively. Normal levels of CD3 þ T cells (X0.9 Â 10 3 /ml) were attained by day 174 and 195 ( Figure 1a) . CD4 þ cells reached normal levels (X0.55 Â 10 3 /ml) at days þ 236 and þ 438.
Lymphocyte proliferation
Patient 2 showed normal responses to PHA when tested at 19 months. Patient 3 showed subnormal responses to PHA at 7 months, which became normal at 15.5 months.
B cell function and immunoglobulin production
For patient 2, normal levels of immunoglobulin G (X500 mg/dl) were obtained at 8 months (prior to infusion of final IVIG dose) and for patient 3, levels of IgG were not measured until 13 months after BMT (4 months after final IVIG dose), at which point the IgG level was normal. Responses to the T and B cell mitogen, pokeweed mitogen (PWM) were detectable 38% (control) in patient 2 when measured at 19 months and increased to 52% of control by 24 months. Patient 3 had PWM responses 28% control when first measured at 14 months and have not been measured subsequently.
Serology and response to immunizations
Patient 2 was reimmunized at 1 year post BMT with DTaP, IPV, Hib, pneumococcal vaccine, and Hepatitis B vaccine. A positive tetanus titer (1:81) was seen prior to the first immunization and increased to 1:243 by 24 months after BMT. Positive diphtheria titers were seen when measured at 2 years (0.35 IU/ml (normal 40.10)). Pertussis titers remain subnormal when tested at 2 years. Patient 2 has received DTaP, Hib, and Hepatitis B Â 3, IPV and pneumococcal vaccine Â 2, and MMR Â 1. Patient 3 received his initial immunizations at 2 years. Pertussis and diphtheria titers were subnormal when tested at 12 and 24 months, but tetanus titers were positive at 1:243 when measured at 12 and 24 months.
Recovery of naïve T cells
To assess the production of naı¨ve T cells, which are associated with thymic function, the analysis of the proportion of CD4 þ /CD45RA þ and CD4 þ / CD45RO þ cells was performed monthly. A small number (5.1%) of naı¨ve CD4 þ /CD45RA þ cells began to appear at day 184 in patient 3. These cells continued to increase (Figure 1b) , reaching 47% of CD4 þ cells by day þ 317. At day þ 472, CD4 þ /CD45RA þ cells were 65.5% of the population. For patient 2, the first analysis was at day þ 222, with CD4 þ CD45RA þ cells 58% of the total CD4 þ population. This percentage remained constant over the subsequent year.
T cell receptor excision circles (TRECs)
To prove that naı¨ve T cells were of thymic origin, TRECs, a measure of thymic migrants, were assayed serially in peripheral blood mononuclear cells. In patient 2, TRECs were first detected at 4 months, approximately 2.5 months after DLI. Levels continue to increase with 2722 copies per 10 5 cells detected at 19 months. Patient 3 showed declining TRECs until 7 months, after which the level has consistently increased (Figure 1c) . The appearance of TRECs in patient 3 occurred approximately 3.5 months after the final DLI.
T cell receptor diversity
We also assessed T cell receptor (TCR) diversity by measurement of TCR CDR3 sequences approximately 1 year post transplant (Figure 1d) . Both patients showed a normal nonskewed TCRb spectratype pattern with complexity scores that were within the normal range.
Infectious complications
Patient 1 died of CMV pneumonitis approximately 4 months after the second transplant. At the time of death, the patient was 100% donor, but showed no evidence of T cell recovery. Patient 2 experienced no significant infectious complications. Patient 3 experienced seizures approximately 6 months after transplantation due to development of CNS toxoplasmosis. This occurred just prior to the development of normal levels of CD3 þ cells, but prior to Haploidentical transplantation for aplastic anemia P Woodard et al normal levels of CD4 þ cells. The patient made a full recovery after therapy with sulfadiazine, pyrimethamine, and clindamycin.
Discussion
Prior alternative donor transplantation for SAA has been limited by graft rejection, toxicity, and infection. [1] [2] [3] [4] Attempts to decrease toxicity by reduction of TBI dosing has improved outcome for those transplanted within 1 year of diagnosis. 5 For patients who fail to respond to immunosuppressive therapy and lack matched unrelated donors, haploidentical transplantation is a therapeutic alternative. This modality has been limited, however, by decreased rates of engraftment coupled with increased rates of GVHD and toxicity. [11] [12] [13] [14] [15] [16] Recently, CD34 þ selection of large doses of stem cells has been used in patients with malignant and nonmalignant disease without severe GVHD. 6, 8 In this preliminary experience with haploidentical HSCT for refractory SAA, all three patients achieved rapid myeloid engraftment and two survive long term. In retrospect, an antipaternal HLA class I antibody was the likely cause of rejection in patient 1. The development of an anti-HLA antibody was likely due to numerous blood products transfused prior to HSCT. Such antibodies have been associated with rejection of solid organ transplants. [24] [25] [26] Investigators have reported extracorporeal immunoadsorption as a method for decreasing anti-HLA antibodies in organ transplant recipients. 27 In our experience, the use of anti-CD20 antibody and plasmapheresis, followed by reconditioning with fludarabine and TLI led to successful engraftment after a second haploidentical infusion from the same donor.
All three patients tolerated conditioning without significant regimen-related toxicity or GVHD; however, patients 2 and 3 developed declining mixed chimerism requiring intervention. Other investigators have reported stem cell boosts, 28 DLI, 29 or CD34 þ -enriched DLI 30 as an effective therapy for declining donor chimerism, poor graft function, or mixed chimerism. Anti-T cell therapy with ATG and CAMPATH proved ineffective at stabilizing mixed chimerism in patient 2. Low-dose DLI in both patients resulted in improved donor chimerism and eventual conversion to 100% donor chimerism. DLI seemed to have minimal effect on recovery of lymphocyte populations, as CD3 þ T cell population did not recover to normal levels until 3.5-4.5 months later. Frequent measurement (weekly in our patients) of donor chimerism using sensitive techniques are critical for early intervention and successful outcome. Ongoing study of the use of DLI or stem cell boosts in a larger cohort is under investigation at our institution to determine the most effective approach to decrease peritransplant toxicity, while ensuring stable engraftment.
Rapid establishment of a functioning donor-derived immune system is critical to reduce post transplant morbidity and mortality. CD8 þ cells recovered at a rate comparable to that reported by other investigators after T cell-depleted BMT 31, 32 CD19 þ B cells reached normal levels at 2.5-5 months, similar to that reported by Eyrich in a similarly treated group of patients. NK recovery in our study occurred later than that reported by Eyrich, 17 possibly due to the dose and type of ATG or other conditioning agents. Recovery of normal levels of CD4 þ cells was delayed until 8-14 months (Figure 1a) , 33 similar to that reported by Eyrich and Kook. Techniques to accelerate recovery of CD4 þ cells are needed to prevent opportunistic infections such as the fatal CMV seen in patient 1.
Normal in vitro lymphocyte proliferation in response to the T cell mitogen PHA occurred at 16 months. Patient 2 was not tested until 19 months, but demonstrated normal proliferation to PHA at that time. To our knowledge, these data have not been previously reported in children undergoing myeloablative haploidentical BMT.
Normal levels of CD4 þ CD45RA þ cells were seen at 8-10 months in both patients. This likely represented thymic processing of immature donor T lymphocytes. Although naı¨ve cells may have come from reversion from CD4 þ CD45RO þ memory cells, we feel this possibility is unlikely. To prove this, we evaluated the presence of excised episomal DNA by TREC analysis (Figure 1c) . TRECs began to increase at 4-8 months, roughly correlating with the occurrence of CD4 þ CD45RA þ cells. Given the extensive depletion of CD3 þ cells from the graft, it is likely that the few mature T cells infused did not contribute significantly to long-term T cell reconstitution.
TCR diversity, a measure of the ability to respond to diverse antigens, was assessed approximately 1 year post transplant (Figure 1d ). Both patients showed a normal nonskewed TCRb spectratype pattern with normal complexity scores. Future studies will include prospective measurement of TCR diversity.
While this preliminary experience involves only three patients, two of these patients became long-term survivors. We provide the only detailed report of immune reconstitution after haploidentical BMT for patients with SAA. Several important findings should be highlighted. First, rapid trilineage engraftment without significant GVHD may be possible in heavily transfused patients with refractory SAA treated with highly purified haploidentical CD34 þ cells. Secondly, infusion of small numbers of CD3 þ cells can improve donor chimerism and reverse graft failure without GVHD in the context of haploidentical transplantation. Effects on T cell recovery and prevention of infectious complications seem modest if any in our two patients and in the experience of Eyrich. Third, effective immune reconstitution was achieved as measured by naı¨ve T cells, TRECs, and TCR diversity. In our preliminary experience of two patients with refractory SAA, engraftment and immune reconstitution are possible after CD34 þ -selected haploidentical transplantation. However, obstacles such as delayed CD4 þ cell recovery and opportunistic infections remain a problem. Careful monitoring for changes in chimerism and infectious pathogens is required. We are prospectively studying this approach for children with aplastic anemia at our institution.
